Non-small cell lung carcinoma (NSCLC)
Clinical trials for Non-small cell lung carcinoma (NSCLC) explained in plain language.
Never miss a new study
Get alerted when new Non-small cell lung carcinoma (NSCLC) trials appear
Sign up with your email to follow new studies for Non-small cell lung carcinoma (NSCLC), keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
New drug combo shows promise in lung cancer battle
Disease control OngoingThis study tested whether a combination of two immunotherapy drugs (durvalumab and tremelimumab) works better than standard chemotherapy for people with advanced non-small cell lung cancer. About 950 adults with stage IV lung cancer who had not received prior treatment took part.…
Matched conditions: NON-SMALL CELL LUNG CARCINOMA (NSCLC)
Phase 3 • Sponsor: AstraZeneca • Aim: Disease control
Last updated Aug 08, 2026 00:03 UTC
-
New drug combo shows promise in lung cancer fight
Disease control OngoingThis study tested two immunotherapy drugs (durvalumab and tremelimumab) alone or together against standard chemotherapy for people with advanced non-small cell lung cancer. Over 1,100 adults with no prior treatment took part. The goal was to see if the new treatments helped peopl…
Matched conditions: NON-SMALL CELL LUNG CARCINOMA (NSCLC)
Phase 3 • Sponsor: AstraZeneca • Aim: Disease control
Last updated Aug 08, 2026 00:03 UTC
-
Immunotherapy shows promise as First-Line attack on tough lung cancer
Disease control OngoingThis study compares a drug called durvalumab (an immunotherapy that helps the immune system fight cancer) to standard chemotherapy as the first treatment for people with advanced non-small cell lung cancer that has high levels of a protein called PD-L1. About 669 adults with stag…
Matched conditions: NON-SMALL CELL LUNG CARCINOMA (NSCLC)
Phase 3 • Sponsor: AstraZeneca • Aim: Disease control
Last updated Jun 27, 2026 13:06 UTC